ALKEON CAPITAL MANAGEMENT LLC 13D and 13G filings for ORIC Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-13 09:42 am Purchase | 2024-09-30 | 13G | ORIC Pharmaceuticals, Inc. ORIC | ALKEON CAPITAL MANAGEMENT LLC | 3,904,096 5.500% | 300,000 (+8.32%) | Filing |
| 2024-02-13 6:43 pm Purchase | 2023-12-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC | ALKEON CAPITAL MANAGEMENT LLC | 3,604,096 6.600% | 1,204,844 (+50.22%) | Filing |
| 2023-02-13 10:15 am Purchase | 2022-12-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC | ALKEON CAPITAL MANAGEMENT LLC | 2,399,252 6.100% | 2,399,252 (New Position) | Filing |